Agennix AG / Agennix AG Announces Longer-Term Mortality Results from Talactoferrin Phase 2 Trial in Severe Sepsis processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

    Trial results show effect of talactoferrin on reduction in mortality is
                   sustained at three months and six months



Martinsried/Munich (Germany), Princeton, NJ and Houston, TX, February 26, 2010 -
Agennix AG (Frankfurt Stock Exchange: AGX) today announced longer-term mortality
results  from  the  talactoferrin  randomized,  double-blind, placebo-controlled
Phase 2 trial in severe sepsis. The trial evaluated talactoferrin versus placebo
in  190 adult patients with severe sepsis  enrolled at 25 leading centers across
the  U.S. Patients in both  arms received standard of  care treatment for severe
sepsis  in an  intensive care  unit (ICU)  setting. As  previously reported, the
trial   achieved  its  primary  endpoint  of  a  reduction  in  28-day all-cause
mortality.  The results announced  today showed that  talactoferrin also reduced
all-cause  mortality compared to placebo over the  longer term - at three months
and at six months.



Three-month  all-cause mortality was 29.3% in the placebo arm compared to 18.1%
in the talactoferrin arm, an absolute reduction of 11% and relative reduction of
38% (unadjusted  two-tailed p-value  = 0.07, odds  ratio by  logistic regression
analysis = 0.53). When the results were adjusted for cardiovascular dysfunction,
a  major prognostic factor for severe  sepsis, the two-tailed p-value was 0.09,
and the odds ratio was 0.55.



At  six months,  there was  a statistically  significant reduction  in all-cause
mortality  from 35.2% in the  placebo arm to  21.3% in the talactoferrin arm, an
absolute  reduction of 14% and relative  reduction of 39% (unadjusted two-tailed
p-value  =  0.04, odds  ratio  =  0.50; adjusted two-tailed p-value = 0.05, odds
ratio  = 0.51). The absolute reduction in  six-month all-cause mortality of 14%
was  greater  than  the  absolute  reduction  seen in 28-day all-cause mortality
(which  was 12%, from  26.6% in the  placebo arm  to 14.6% in  the talactoferrin
arm).


The  results  for  three-  and  six-month  all-cause mortality in the study were
consistent   and   sustained   for  patients  with  and  without  cardiovascular
dysfunction.



 "We  are extremely pleased to see that the treatment effect of talactoferrin in
severe  sepsis appears to be  sustained over a longer  time period," said Rajesh
Malik,  M.D., Chief Medical Officer. "There are currently very limited treatment
options available, with only one drug approved specifically for severe sepsis, a
disease  that results in hundreds  of thousands of deaths  each year in the U.S.
and  Europe alone. We plan  to meet with regulatory  authorities within the next
few months to discuss plans for advancing talactoferrin for this indication."



The  above analyses  were all  conducted on  an intent-to-treat (ITT) as-treated
basis, meaning that patients were evaluated based on the treatment they actually
received (talactoferrin or placebo).



Talactoferrin  was shown to  be very well  tolerated in the  study with no major
differences in adverse events between the two treatment arms.



The  Phase  2 trial  was  primarily  funded  by  a  grant from the U.S. National
Institutes of Health.



The  Company plans to present  data from the trial  at an upcoming major medical
meeting.



About severe sepsis

Sepsis  is a  condition involving  known or  suspected infection and generalized
inflammation. The body's normal response to an infection is to set off a limited
chain  reaction to fight the infection. In severe sepsis, this systemic response
escalates  into an overreaction by the body  that leads to dysfunction of one or
more  organs. Each year, approximately 750,000 people  in the U.S. alone develop
severe  sepsis, and  a similar  number of  people are  affected in Europe. Those
figures  are expected  to rise  due to  the aging  population and other factors.
Approximately  30-40% of people with severe sepsis are estimated to die annually
from  this condition in the  U.S., and the U.S.  Centers for Disease Control and
Prevention  indicates that sepsis is one of  the top ten leading causes of death
in the U.S.



About oral talactoferrin

Talactoferrin  is an oral novel targeted  dendritic cell recruiter and activator
being   studied   mainly   for  the  treatment  of  cancer  and  severe  sepsis.
Talactoferrin   has   demonstrated   activity   in   randomized,   double-blind,
placebo-controlled Phase 2 studies in non-small cell lung cancer (NSCLC) as well
as  in severe sepsis.  As a result  of the promising  results from Phase 2 NSCLC
studies,  two Phase 3 studies  have been initiated  with talactoferrin in NSCLC.
The  Company is planning to  meet with regulatory authorities  to discuss a plan
for the further development of talactoferrin for the treatment of severe sepsis.
Talactoferrin  has  been  shown  to  be  very  well  tolerated  in these patient
populations.



About Agennix

Agennix  AG is  a publicly  traded biopharmaceutical  company that is developing
novel  therapies in areas of major unmet  medical need to improve the length and
quality  of life of seriously ill  patients. The Company's most advanced program
is  talactoferrin, an  oral targeted  therapy that  has demonstrated activity in
randomized,  double-blind, placebo-controlled Phase  2 studies in non-small cell
lung  cancer as well as in severe sepsis. Talactoferrin is currently in Phase 3
clinical  trials  in  non-small  cell  lung  cancer.  Other clinical development
programs  include  RGB-286638,  a  multi-targeted  kinase  inhibitor in Phase 1
testing; the oral platinum-based compound satraplatin; and a topical gel form of
talactoferrin  for  diabetic  foot  ulcers.  Agennix's  registered  seat  is  in
Heidelberg,    Germany.    The   Company   has   three   sites   of   operation:
Martinsried/Munich,  Germany;  Princeton,  New  Jersey  and  Houston, Texas. For
additional information, please visit the Agennix Web site at www.agennix.com.



This  press  release  contains  forward-looking  statements,  which  express the
current  beliefs  and  expectations  of  the  management  of  Agennix  AG.  Such
statements  are  based  on  current  expectations  and  are subject to risks and
uncertainties,  many of  which are  beyond our  control, that could cause future
results,  performance or achievements to  differ significantly from the results,
performance  or  achievements  expressed  or  implied  by  such  forward-looking
statements.  There can be no guarantee  that the Company will move talactoferrin
forward  in development for severe sepsis in a timely manner, if at all, or that
talactoferrin  will  ultimately  be  approved  for  sale  in any country. Actual
results could differ materially depending on a number of factors, and we caution
investors  not  to  place  undue  reliance  on  the  forward-looking  statements
contained in this press release. Forward-looking statements speak only as of the
date on which they are made and Agennix undertakes no obligation to update these
forward-looking  statements, even  if new  information becomes  available in the
future.





For further information, please contact:




Agennix
AG

Investor Relations & Corporate Communications

Phone: +49 (0)89
8565 2693

ir@agennix.com




In the U.S.: Laurie
Doyle

Director, Investor Relations & Corporate Communications

Phone: +1 609 524 5884


laurie.doyle@agennix.com












Additional media contacts for Europe:

MC Services
AG

Phone: +49 (0) 89 210 228 0



Raimund
Gabriel

raimund.gabriel@mc-services.eu




Hilda
Juhasz

hilda.juhasz@mc-services.eu





Additional investor contact for Europe:

Trout International
LLC

Lauren Williams, Vice President

Phone: +44 207 936 9325

lwilliams@troutgroup.com








[HUG#1388902]



 --- End of Message --- 

Agennix AG
Fraunhoferstr. 20 Martinsried Germany

ISIN: DE000A1A6XX4;
Listed: Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;